Shares of Apyx Medical Corporation (NASDAQ:APYX - Get Free Report) have earned an average rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $6.20.
Several analysts have commented on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Apyx Medical in a research note on Monday, September 21st. Maxim Group initiated coverage on Apyx Medical in a research note on Tuesday, September 29th. They set a "buy" rating and a $6.00 price target on the stock.
View Our Latest Stock Analysis on APYX
Institutional Investors Weigh In On Apyx Medical
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Nwam LLC purchased a new position in Apyx Medical during the first quarter worth about $47,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Apyx Medical in the 2nd quarter worth about $62,000. AXQ Capital LP acquired a new stake in Apyx Medical in the 2nd quarter worth about $78,000. HighTower Advisors LLC purchased a new stake in Apyx Medical in the 3rd quarter valued at about $51,000. Finally, Jefferies Financial Group Inc. acquired a new position in shares of Apyx Medical during the 2nd quarter valued at about $110,000. Hedge funds and other institutional investors own 55.33% of the company's stock.
Apyx Medical Stock Performance
NASDAQ:APYX opened at $2.81 on Monday. The firm has a 50 day simple moving average of $2.72 and a 200-day simple moving average of $3.55. The company has a debt-to-equity ratio of 3.54, a current ratio of 4.95 and a quick ratio of 3.85. The firm has a market cap of $118.37 million, a PE ratio of -14.79 and a beta of 1.47. Apyx Medical has a 1-year low of $2.25 and a 1-year high of $5.08.
Apyx Medical (NASDAQ:APYX - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.05. Apyx Medical had a negative net margin of 14.16% and a negative return on equity of 68.79%. The business had revenue of $14.03 million for the quarter, compared to the consensus estimate of $13.29 million. On average, equities analysts expect that Apyx Medical will post -0.21 EPS for the current year.
About Apyx Medical
(
Get Free Report)
Apyx Medical Corporation is a medical technology company focused on advanced energy devices for surgical and aesthetic procedures. Its main product is the Renuvion system, which combines helium plasma with radiofrequency energy for use in procedures covered by applicable regulatory clearances. The company also supplies electrosurgical generators and related products, including through its original equipment manufacturing business. Apyx Medical was formerly known as Bovie Medical Corporation and adopted its current name in 2018.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Apyx Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apyx Medical wasn't on the list.
While Apyx Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.